• Vaccine Name: C. muridarum PmpG-1 protein vaccine
• Target Pathogen: Chlamydia muridarum
• Vaccine Ontology ID: VO_0011458
• Type: Subunit vaccine
• Status: Research
• Antigen: C. muridarum polymorphic membrane protein G family protein
• PmpG-1 gene engineering:
  • Type: Recombinant protein preparation
  • Description: The source proteins containing the MHC II binding Chlamydia peptides were cloned, expressed and purified as follows: pmpG-1 and gap DNA fragments were generated by PCR using genomic DNA isolated from C. muridarum. The PCR products were purified and cloned into pET32a (Novagen) for pmpG-1 and gap after restriction enzyme digestion with BamHI/NotI using standard molecular biology techniques. Only the first half of the gene (25–500) was cloned into the vector for expression (Yu et al., 2009).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000142
  • Description: Incomplete Freunds Adjuvant (Sigma)
• Immunization Route: Intravenous injection (i.v.)

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Mice were vaccinated three times with a 2-week interval, intravenously (i.v.) into the tail veins with 1 × 10^6 DCs transfected with Chlamydia protein PmpG-1 25–500 in 200 μl of PBS. DCs pulsed with live EB or GST protein was used as positive or negative controls respectively (Yu et al., 2009).
• Challenge Protocol: Two weeks after the final immunization, five to ten mice from each group were intranasally (i.n.) challenged with 2000 IFU of C. muridarum. Weight loss was monitored each or every two days. On 10 day after i.n. challenge, the mice were euthanized and the lungs were collected for Chlamydia titration (Yu et al., 2009).
• Efficacy: Overall, vaccination with DCs transfected with PmpG-1(25-500) exhibited the greatest degree of protective immunity among the four Chlamydia Ags tested (Yu et al., 2009).